Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Completed Phase 1 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0029297 (Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00994500Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaTreatment